111 views
0

WHY THIS MATTERS IN BRIEF

As researchers continue to develop micro-machines and implanted medical devices that live within our bodies we might need to find new ways to power them.

 

Humanity has been generating electricity from flowing water for millennia using everything from watermills to huge hydro-electric dams, but now researchers in China have given new meaning to the decades old saying “There’s electricity in our veins,” and have managed to scale this machinery down to a size small enough to generate electrical power from something much much smaller – the blood running through our bodies.

 

RELATED
Chip sized particle accelerators will make renewable energy even cheaper

 

Using principles similar to those used in some of the world’s largest hydro-electric dams a team of Chinese researchers from Fudan University have built a tiny, one dimensional nanogenerator that’s designed to sit inside veins and generate electricity from the flow of blood. And this isn’t the first time researchers have toyed with turning our blood streams into next generation energy sources – back in 2011 a team of Swiss researchers developed tiny turbines that generated electricity from the blood in human arteries but it had a flaw, it created lethal blood clots… and let’s face it that’s a really bad flaw.

The Chinese teams device, which was successfully tested on frogs, and which doesn’t cause blood clots, is less than half a micron in size and uses “an orderly array of carbon nanotubes wrapped around a polymeric core to generate power” using what the team call a “Fiber Fluidic Nanognerator,” or FFNG for short.

 

RELATED
Scientists have designed a nanoscale computer that's smaller than a virus

 

“The electricity is generated by the movement between the FFNG and the blood,” said Huisheng Peng who led the research, “an electrical double layer is created around the fiber, and then the flowing solution distorts the symmetrical charge distribution, generating an electricity gradient along the devices long axis.”

At the moment it’s not clear how much power the device can generate, but the team claim it is “high” compared to other miniature energy harvesting devices and that it has a power conversion efficient of more than 20 percent, and while the technology is still in its early stages the team are hopeful that one day the device could be used to power insulin pumps, pace makers and other implanted medical devices in people’s bodies. And who knows, maybe one day they’ll sit alongside the other nanobots in our bloodstreams as they hunt down disease and kill cancer from within, or power our bodies when we turn them into the next generation of chemical computers, and who’s to say that the blood in our blood streams won’t be artificial… but all that’s another story.

The research was published in the journal Angewandte Chemie.

About author

Matthew Griffin

Matthew Griffin, award winning Futurist and Founder of the 311 Institute, a global futures think tank, is described as "The Adviser behind the Advisers." Regularly featured on AP, CNBC, Discovery and RT, his ability to identify and track hundreds of game changing emerging technologies, and explain their impact on global culture, industry and society, is unparalleled. Recognised for the past five years running as one of the world's foremost futurists, innovation and strategy experts Matthew is an international speaker who helps governments investors, multi-nationals and regulators around the world envision, build and lead an inclusive future. A rare talent Matthew sits on the Technology and Innovation Committee (TIAC) for Centrica, one of Europe’s largest energy companies, and his recent work includes mentoring XPRIZE teams, building the first generation of biocomputers, helping the world’s largest manufacturers companies envision the next five generations of smartphones and devices, and what comes next, and helping companies including Qualcomm envision the next twenty years of semiconductors. Matthew's clients are the who’s who of industry and include Accenture, Bain & Co, BOA, Blackrock, Bloomberg, Booz Allen Hamilton, BCG, Bentley, Dell EMC, Dentons, Deloitte, Deutsche Bank, Du Pont, E&Y, Fidelity, Goldman Sachs, HPE, Huawei, JPMorgan Chase, KPMG, Lloyds Banking Group, McKinsey, Monsanto, PWC, Qualcomm, Rolls Royce, SAP, Samsung, Schroeder's, Sequoia Capital, Sopra Steria, UBS, the UK's HM Treasury, the USAF and many others.

Your email address will not be published. Required fields are marked *